RecruitingAsthma

Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Reslizumab is a type of medicine called a monoclonal antibody that is made in the research clinic; it works by blocking a specific protein in the body called interleukin-5. The study medicine, reslizumab, is not yet approved for doctors to treat patients with EGPA. It is considered an experimental drug in this study.

Sponsor: National Jewish Health

You may qualify if…

✓ Informed Consent: Able to give written informed consent prior to participation in the study, which will include the ability to comply with the requirements and restrictions listed in the consent form. Subjects must be able to read, comprehend, and write at a level sufficient to complete study related materials.
✓ Gender and Age: Male or female subjects \>18 years old
✓ EGPA diagnosis: subjects who have been diagnosed with EGPA for at least 6 months based on the history or presence of: asthma plus eosinophilia (\>1.0x109/L and/or \>10% of leucocytes) plus at least two of the following additional features of EGPA:
✓ A biopsy showing histopathological evidence of eosinophilic vasculitis, or perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation;
✓ Neuropathy, mono or poly (motor deficit or nerve conduction abnormality);
✓ Pulmonary infiltrates, non-fixed;
✓ Sino-nasal abnormality;
✓ Cardiomyopathy (established by echocardiography or MRI);

You may not qualify if…

✕ Hypereosinophilic Syndrome
✕ Wegener's Granulomatosis
✕ Malignancy
✕ Parasitic disease
✕ Pregnant or nursing
✕ If female and of child-bearing potential, must have negative pregnancy test and must adhere to acceptable method of contraception (with \<1% failure rate) during the study and for four months after the study.
✕ Any other medical illness that precludes study involvement
✕ Patients who are currently receiving or have previously received reslizumab or any other type of anti-interleukin therapy (i.e. mepolizumab, lebrikizumab etc.) within the last three months.

Where it's recruiting

Colorado

Denver

Source: ClinicalTrials.gov · NCT02947945 · last updated 2017-09-14